Affiliations 

  • 1 Department of Urology. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • 2 Department of Urology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea
  • 3 Real World Evidence, IQVIA, Petaling Jaya, Malaysia
  • 4 Medical Affairs, Astellas Pharma Singapore Pte. Ltd, Singapore, Singapore
  • 5 Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea
Neurourol Urodyn, 2021 11;40(8):1972-1980.
PMID: 34486168 DOI: 10.1002/nau.24776

Abstract

AIMS: To descriptively evaluate treatment persistence among adults who received mirabegron or antimuscarinics in South Korea.

METHODS: This study involved a retrospective analysis of the Health Insurance Review and Assessment (HIRA) database. Patients (≥18 years) who had a new prescription for an overactive bladder (OAB) target medication (mirabegron/antimuscarinic) within an 8-month index period (July 1, 2015-February 29, 2016) were included. The date when the target (index) medication was dispensed was the index date. The 6-month period before the index date was used to assess patient eligibility. A 12-month post-index period was used to assess medication persistence, which was defined as the time to discontinuation. Overall data were analyzed and the results were also stratified by age group (≤65, >65 years), sex, or prior OAB medication experience. Persistence rates were calculated after the 1st, 3rd, 6th, 9th, and 12th months.

RESULTS: A data set of 52 722 cases was obtained (mirabegron: 11 424, antimuscarinics: 41 298). The mean age was 60.9 ± 16.1 years and the majority of the patients were female (30 862 [58.5%] patients). Median persistence was longer with mirabegron (51 days) versus antimuscarinics (25 days). The persistence rate with mirabegron was higher throughout the study compared with all the antimuscarinics (12-month data: 13.5% and 4.9%, respectively). Longer treatment persistence was noted in older, male, and treatment-experienced patients.

CONCLUSION: The results from the HIRA database showed that persistence was longer with mirabegron than with antimuscarinics in South Korea. This finding may help inform clinical decision-making within the South Korean healthcare system.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.